Outside Anchorage

Two Cases of Rheumatic Fever in Alaska, 2009–2010

Introduction
Since the 1950s, the incidence of rheumatic fever (RF), a sequela of group A streptococcal pharyngitis, has decreased sharply. Nevertheless, RF remains a leading cause of acquired heart disease in the developing world. Several environmental and social determinants of RF, including limited health care resources, are prevalent in Alaska. During 2000–2010, RF cases were reported in Alaska during all but 3 years (Figure). In November 2010, the Section of Epidemiology (SOE) was notified of two cases of RF. The purpose of this Bulletin is to describe these cases, to provide current guidelines for diagnosis and treatment, and to remind clinicians to report all suspected and confirmed RF cases to SOE to facilitate prompt outbreak detection and response.

Figure. Reported Rheumatic Fever Cases in Alaska, 2000–2010

Case Reports
Patient A. On June 27, 2009, a previously healthy adolescent female Pacific Islander was seen in the Providence Alaska Medical Center (PAMC) emergency department (ED) complaining of “twitching” in her left arm and leg. Patient A was discharged from the ED and referred for follow-up with a neurologist. On July 10, Patient A was admitted to PAMC following a second ED visit with a diagnosis of “possible chorea.” On admission, the attending neurologist noted numerous “choreoathetoid movements” that were especially prominent distally. Despite the absence of a murmur by the attending cardiologist, the attending neurologist noted abnormal movements in her extremities for approximately two months. On exam, she had choreiform movements. She had an elevated erythrocyte sedimentation rate (ESR). A follow-up antibody test performed 3–4 weeks after RF symptom onset is recommended to confirm the presence of streptococcal pharyngitis.

Patient B. On October 12, 2010, a previously healthy adolescent Alaska Native female was referred to the Alaska Native Medical Center (ANMC) for neurologic and cardiac evaluation after choreiform movements were observed by her primary care provider. Patient B reported experiencing abnormal movements in her extremities for approximately two months, and had a history of recurrent streptococcal infections. On exam, she had choreiform movements. She had elevated erythrocyte sedimentation rate (ESR). An echocardiogram on October 18 showed an abnormal mitral valve with thickened distal leaflets and mild-to-moderate mitral insufficiency. The cardiologist concluded that Patient B’s history was consistent with RF and prescribed intramuscular bICillin and aspirin.

Discussion
Rheumatic fever is an uncommon and serious sequela of group A Streptococcus pyogenes (GAS) infection that can result in considerable morbidity and mortality. Appropriate treatment of streptococcal pharyngitis reduces the risk of RF.

A diagnosis of a primary episode of RF requires that a patient have either two major criteria, or one major and two minor criteria, plus evidence of previous GAS infection (Table). Evidence of previous infection can include a positive culture or rapid test, recent scarlet fever, a prolonged P-R interval on electrocardiogram, or an elevated/increasing streptococcal antibody test. A follow-up antibody test performed 3–4 weeks after RF symptom onset is recommended to confirm the previous streptococcal infection.

Table. Jones Criteria for the Diagnosis of Rheumatic Fever

<table>
<thead>
<tr>
<th>Major Criteria</th>
<th>Minor Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carditis</td>
<td>Arthralgia</td>
</tr>
<tr>
<td>Polyarthritis</td>
<td>Fever</td>
</tr>
<tr>
<td>Subcutaneous nodules</td>
<td>Laboratory results suggesting</td>
</tr>
<tr>
<td>Chorea</td>
<td>acute inflammation (e.g., Erythema marginatum elevated WBC count or ESR)</td>
</tr>
</tbody>
</table>

WBC=white blood cell; ESR=erythrocyte sedimentation rate

Recommendations
1. If a patient is suspected of having RF, evaluate evidence of previous GAS infection (see Discussion above). Laboratory tests for markers of inflammation are also useful (Table).

2. Consider ordering an echocardiogram to evaluate for subclinical valvulitis.

3. A patient with irregular movement should be evaluated by someone aware of the clinical appearance of Sydenham’s chorea to avoid confusion with other conditions where positive GAS serology is an unrelated finding.

4. Because cardiac sequelae can develop after a movement disorder, re-evaluation of cardiac health 3–6 months after the development of irregular movements may be prudent.

5. The recommended treatment for RF includes anti-inflammatory therapy (e.g., an analgesic, aspirin, or prednisone, depending on clinical severity) and inflammatory therapy (e.g., an analgesic, aspirin, or prednisone, depending on clinical severity) and intramuscular benzathine penicillin G every 4 weeks to prevent additional attacks. The penicillin dosing should be 1.2 million units for persons weighing ≥67 kg, or 600,000 units for persons weighing ≤67 kg. The duration of therapy depends on the degree of cardiac involvement during the most recent attack.

6. Rheumatic fever is reportable to SOE by health care providers (7 ACC 27.005). To report, please call 907-269-8000, 561-4234, or 1-800-478-1700 if outside Anchorage, or fax information to 907-561-4239.

Acknowledgements
We thank Drs. Rosalyn Singleton and Rod Smith for providing technical edits for this Bulletin.

References